Phase Ib trial of erdafitinib (E) combined with enfortumab vedotin (EV) following platinum and PD-1/L1 inhibitors for metastatic urothelial carcinoma (mUC) with FGFR2/3 genetic alterations (GAs). Meeting Abstract

International Collaboration

cited authors

  • Jain, Rohit K.; Heiligh, Jazlyn; Kim, Youngchul; Piekarz, Richard; Pelosof, Lorraine Cheryl; Yang, Yuanquan (Aaron); D'souza, Anishka; Wong, Risa Liang; Graham, Laura; Gupta, Sumati; Park, Anna; Synold, Timothy W.; Sonpavde, Guru P.

Publication Date

  • February 1, 2024

webpage

published in

category

keywords

  • 1
  • 130-540-543-12277-2683
  • 2
  • 261-492-2769
  • 261-492-5651-9270-5652
  • 283-183-138-11076
  • 2947
  • 3
  • 3224
  • 4
  • 6
  • 613-225-2577-2526
  • 613-225-2782
  • 613-225-325
  • 613-3267-6252-2353
  • 62

start page

  • 625

end page

  • 625

volume

  • 42

issue

  • 4_SUPPL